These findings collectively suggest that combining KLK7 inhibitors with immune checkpoint inhibitors could be explored as a strategy to modulate the tumor immune microenvironment and enhance the efficacy of immunotherapy in PTC patients. The gene discussed is KLK7; the disease is neoplasm.